Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01447
|
|||||
| Drug Name |
E3040
|
|||||
| Synonyms |
E-3040; E 3040; CHEMBL105139; 145096-30-6; E3040; AC1L9EDQ; CHEBI:4732; 6-Hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole; SCHEMBL6009376; DTXSID80162877; CHEBI:271098; 5,7-Dimethyl-2-(methylamino)-4-(3-pyridinylmethyl)-6-benzothiazolol; BDBM50037037; 6-Benzothiazolol, 5,7-dimethyl-2-(methylamino)-4-(3-pyridinylmethyl)-; C11593; L001447; 5,7-Dimethyl-2-methylamino-4-pyridin-3-ylmethyl-benzothiazol-6-ol; 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Thrombosis [ICD11: BD71.4, BD72] | Discontinued in Phase 2 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C16H17N3OS
|
|||||
| Canonical SMILES |
CC1=C(C2=C(C(=C1O)C)SC(=N2)NC)CC3=CN=CC=C3
|
|||||
| InChI |
InChI=1S/C16H17N3OS/c1-9-12(7-11-5-4-6-18-8-11)13-15(10(2)14(9)20)21-16(17-3)19-13/h4-6,8,20H,7H2,1-3H3,(H,17,19)
|
|||||
| InChIKey |
IONAQTGMWFXHIX-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 145096-30-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 299.4 | Topological Polar Surface Area | 86.3 | ||
| Heavy Atom Count | 21 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
3.9
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:4732
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005994) | |||||
| 2 | Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005 May 11;7(1):E118-33. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.